-
Zoloft, the antidepressant, and Norvasc, its big-selling hypertension drug, were the culprits in the second quarter.
FORBES: Magazine Article
-
Ranexa was tested on top of Norvasc in patients who were already benefiting the most from that drug.
FORBES: A Biotech's Big Comeback
-
But it is facing similar problems, as big-selling drugs like Zoloft, for depression, and Norvasc, for hypertension, lose patent protection.
FORBES: Magazine Article
-
Recently, Pfizer lost a case related to a patent for Norvasc, shaving six months off the life of the hypertension treatment.
FORBES: Magazine Article
-
But the patent on combining Norvasc and Caduet lasts until 2018.
FORBES: Pfizer Wins Longer Life For Lipitor
-
The biggest controversy is whether Pfizer will spin off its established products unit, which sells generic drugs and branded medicines like Norvasc and Zoloft that have lost patent protection.
FORBES: Why Pfizer Will Break Up
-
India's Dr. Reddy's Laboratories (nyse: RDY - news - people ) looks ready to bring a so-called branded generic version of Norvasc, Pfizer's best-selling hypertension medicine, to market.
FORBES: Pfizer's Next Move
-
Too bad Norvasc loses patent protection next year.
FORBES: Are Drug Patents Too Short?
-
Caduet will also provide another big benefit for patients with health insurance: Because it is a single pill, patients will get both drugs for a single co-payment, making it inexpensive for them even after Norvasc becomes a cheap generic.
FORBES: Magazine Article